Merck Announces $5 Billion Accelerated Share Repurchase
News May 22, 2013
Proceeds from the company’s recently concluded debt offering were used to execute the ASR, which is part of Merck’s previously announced $15 billion share repurchase program.
“This accelerated share repurchase demonstrates our commitment to delivering increased value to shareholders in the short term, while continuing to invest in the important opportunities that will drive our long-term growth,” said Kenneth C. Frazier, chairman and chief executive officer, Merck.
Under the terms of the ASR, Merck has agreed to repurchase $5 billion of its common stock from Goldman, Sachs & Co., in total, with an initial delivery of approximately 99.5 million shares based on current market prices. The final number of shares to be repurchased will be based on Merck’s volume-weighted average stock price during the term of the transaction, which is expected to be completed no later than November 25, 2013.
In the first four months of 2013, Merck repurchased approximately 17.8 million shares for a total of $772 million. As of April 30, 2013, the company’s total outstanding share repurchase authorization was $16.1 billion, which included $1.1 billion in authorized repurchases remaining under the program previously announced on April 27, 2011.
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE
Disease-Fighting 'Warheads' Hidden in BacteriaNews
Bacteria found in soil may harbor a potential game-changer for drug design. A new study by Scripps Research, published today in Nature Communications, suggests scientists could build better drugs by learning from bacteria-derived molecules called thiocarboxylic acids.READ MORE
Exploring Challenges in the Synthesis of Pharmaceutical DrugsNews
This summer, Wendell and Loretta Hess Professor of Chemistry Ram Mohan will travel to India and Hong Kong to deliver a series of post-graduate workshops on advanced concepts in organic synthesis.
His workshop “Advanced Concepts in the Synthesis of Pharmaceutical Drugs” at the Indian Institute of Technology Indore will explore the unique, real-world challenges in the pharmaceutical industry to synthesize drugs that are both commercially viable and eco-friendly.
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018